Bryan, Garnier & Co Reaffirms “Buy” Rating for AstraZeneca (AZN)

Bryan, Garnier & Co reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research note published on Friday morning.

A number of other research analysts have also issued reports on the company. Citigroup reiterated a buy rating on shares of AstraZeneca in a research report on Thursday, September 7th. Natixis upgraded AstraZeneca from a neutral rating to a buy rating and boosted their price target for the stock from GBX 5,000 ($67.29) to GBX 5,738 ($77.23) in a research report on Wednesday, September 6th. Deutsche Bank reiterated a buy rating and set a GBX 5,300 ($71.33) price target on shares of AstraZeneca in a research report on Tuesday, September 5th. Liberum Capital reiterated a buy rating and set a GBX 4,800 ($64.60) price target on shares of AstraZeneca in a research report on Tuesday, September 5th. Finally, Societe Generale reiterated a buy rating on shares of AstraZeneca in a research report on Monday, September 11th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and a consensus target price of GBX 5,169 ($69.57).

AstraZeneca (LON:AZN) opened at GBX 4,886.50 ($65.77) on Friday. AstraZeneca has a 12-month low of GBX 4,136.50 ($55.67) and a 12-month high of GBX 5,520 ($74.29).

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/12/18/bryan-garnier-co-reaffirms-buy-rating-for-astrazeneca-azn.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply